Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0147 -0.0015 (-9.26%)

Streaming Delayed Price Updated: 3:23 PM EDT, Mar 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	62,262
Open	0.0163
Bid (Size)	0.0132 (500)
Ask (Size)	0.0200 (5,000)
Prev. Close	0.0162
Today's Range	0.0147 - 0.0163
52wk Range	0.0100 - 0.0899
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

March 19, 2026

Via ACCESS Newswire

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

March 17, 2026

Via ACCESS Newswire

Performance

YTD	-21.0%	-21.0%
1 Month	-16.9%	-16.9%
3 Month	-33.8%	-33.8%
6 Month	-28.6%	-28.6%
1 Year	-71.7%	-71.7%

More News

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

March 12, 2026

Via ACCESS Newswire

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

March 10, 2026

Via ACCESS Newswire

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

March 03, 2026

Via ACCESS Newswire

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

February 25, 2026

Via ACCESS Newswire

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

February 20, 2026

Via ACCESS Newswire

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

February 19, 2026

Via ACCESS Newswire

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

February 17, 2026

Via ACCESS Newswire

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

February 13, 2026

Via ACCESS Newswire

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

February 12, 2026

Via ACCESS Newswire

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

February 11, 2026

Via ACCESS Newswire

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

February 10, 2026

Via ACCESS Newswire

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

February 05, 2026

Via ACCESS Newswire

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

February 03, 2026

Via ACCESS Newswire

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

January 22, 2026

Via ACCESS Newswire

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

January 21, 2026

Via ACCESS Newswire

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

January 20, 2026

Via ACCESS Newswire

Aspire Biopharma Announces Reverse Stock Split

January 14, 2026

Via ACCESS Newswire

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

January 07, 2026

Via ACCESS Newswire

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

December 18, 2025

Via ACCESS Newswire

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

December 12, 2025

Via ACCESS Newswire

Aspire Biopharma Provides Q3 2025 Business Update

December 04, 2025

Via ACCESS Newswire

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

December 02, 2025

Via ACCESS Newswire

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

November 26, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Aspire Biopharma Holdings, Inc. - Warrant publicly traded?

Yes, Aspire Biopharma Holdings, Inc. - Warrant is publicly traded.

What exchange does Aspire Biopharma Holdings, Inc. - Warrant trade on?

Aspire Biopharma Holdings, Inc. - Warrant trades on the Nasdaq Stock Market

What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant?

The ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant is ASBPW on the Nasdaq Stock Market

What is the current price of Aspire Biopharma Holdings, Inc. - Warrant?

The current price of Aspire Biopharma Holdings, Inc. - Warrant is 0.0147

When was Aspire Biopharma Holdings, Inc. - Warrant last traded?

The last trade of Aspire Biopharma Holdings, Inc. - Warrant was at 03/27/26 03:23 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.